

EFECTELE ADVERSE INDUSE DE MEDICAȚIA PSIHOTROPĂ

Academician Prof. Univ. Dr. Dragoș Marinescu

Specializare psihofarmacologie clinică

UMF Craiova, Școala Doctorală

Spital Clinic de Neuropsihiatrie, Clinica de psihiatrie I, Craiova

Craiova 17.09.2019

Psihofarmacologie clinică – eficiență

- Integritatea structurală și funcțională a SNC
- Reacții adverse
- Interacțiuni medicamentoase

Particularități ale siguranței și eficacității terapiei în psihofarmacologie

- Integritatea BHE
- Reacția inflamatorie, raportul neuron/activare microglială
- Calitatea perfuziei sangvine cerebrale
- Integritatea funcțională hepatică
- Suport metabolic cerebral
- Integritatea funcțională a pompei cardiace
- Integritatea funcțională renală
- Brain - gut microbioma axis
- Comorbidități
- Patologia duală

SIGURANȚA TERAPIEI PSIHOTROPE ESTE DEPENDENTĂ DE:

Precocitatea diagnosticului


Corectitudinea diagnosticului

Calitatea și completitudinea remisiunilor

Aderența și complianța la tratament

EFECTE ADVERSE SEVERE CARE PUN ÎN PERICOL VIAȚA PACIENTULUI

- Sindromul serotoninergic
- Sindromul neuroleptic malign
- Hipotensiunea ortostatică
- Prelungirea intervalului QT, aritmii



Drug-Induced Serotonin Syndrome

Dana Bartlett, RN, BSN, MSN, MA, CSPI

Table 1 Agents that cause serotonin syndrome

Amphetamine
Buspirone
Cocaine
Dextromethorphan
Fentanyl
Linezolid
Lysergic acid diethylamide (LSD)
Monoamine oxidase inhibitors (MAOIs)
3,4-Methylene dioxymethamphetamine (MDMA; ecstasy)
Methylene blue
Ondansetron
Selective serotonin reuptake inhibitors (SSRIs)
Serotonin-norepinephrine reuptake inhibitors (SNRIs)
St John's wort
Sumatriptan
Tramadol
Tricyclic antidepressants
Tryptophan

Table 2 Mechanisms of action of serotonin syndrome

Mechanism	Example
Direct serotonin receptor agonism	Buspirone, LSD
Decreased serotonin breakdown	MAOIs, methylene blue
Decreased reuptake of serotonin	Duloxetine, fluoxetine
Increased formation of serotonin	Tryptophan
Increased release of serotonin	Cocaine, fentanyl

Abbreviations: LSD, lysergic acid diethylamide; MAOIs, monoamine oxidase inhibitors.

Based on information from Hillman et al,¹¹ Ables and Nagubilli,¹² and Iqbal et al.¹³

Table 3 Clinical situations in serotonin syndrome

Abuse of illicit drugs
Drug-drug interactions
Intentional overdose of a serotonergic medication
Therapeutic use of a serotonergic medication or medications

Neuroleptic Malignant Syndrome

Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective, Lurdes Tse, Alasdair M Barr, Fidel Vila-Rodriguez, Current neuropharmacology 2015

Risk Factors	
Category	Variable
Pharmacological Treatment	Initial phases of treatment or, change of dosage High dose of AP Parenteral administration (i.v. or i.m.) Polypharmacy Antipsychotic treatment Other compounds: AD, MS, aP
Environmental factors	Physical restraint Dehydration High temperature
Demographics	Age Multimorbidities
Genetic liability	Previous NMS Family history of Catatonic Syndrome Muscle channelopathy

i.v., intravenous; *i.m.*, intramuscular; *AD*, antidepressants; *MS*, mood stabilizers; *AP*, antipsychotics; *aP*, antiparkinsonian

Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management

Indication for treatment with psychiatric medications

A-drugs

(no QT prolongation)

1. Benzodiazepines
2. Mood stabilizers
 - a. Antiepileptics
3. Certain antidepressants
4. Certain antipsychotics

Full list and generics: See table 2

B- and B*-drugs

(possible QT-prolongation or arrhythmia)

1. Antipsychotics
 - a. 1st Generation
 - b. 2nd Generation
2. Mood Stabilizers
 - a. Lithium
3. Antidepressants
 - a. Tricyclic antidepressants
 - b. Monoamine oxidase inhibitors
 - c. Most SSRI
4. Methadone

Full list and generics: See table 2

A-drug

Initiate treatment
- no "Heart check-ups"

Initiate treatment

Heart check-up

1-2 weeks after initiation and after increases in doses $\geq 50\%$ (for methadone ≥ 100 mg/day) assessment of:

- A. New cardiac symptoms?
- B. ECG:
 - a. QTc > 500 ms?
 - b. Δ QTc > 60 ms?

No

Continue treatment
At ordinary psychiatry follow-up – ask about arrhythmia /syncope

Positive findings

B-drug

Assess cardiac risk profile

1. Known cardiac disease, including long QT syndrome
2. Family history; arrhythmia or SCD
3. Other QT prolonging/interacting drugs
4. Hypokalemia (p-K < 3.5 mM)
5. Cardiac symptoms:
 - a. Syncope (unexplained) or b. Palpitations
 - c. Dyspnoea or d. Angina
6. ECG: a. QTc > 480 ms. b. Other findings*
7. Age > 70 years, female sex

Positive findings

Consider assessment by cardiologist before initiation of treatment in order to:

1. Assess/optimize cardiac risk
2. Re-consider choice of drug

1. Cease (or reduce dose) - or
2. Change to different drug (primarily A drug)
3. Continue **ONLY** if no cardiac symptoms, a strong indication and after consultation with a cardiologist
4. If continued – close "Heart check-ups"

*e.g. bundle branch block, AV-block, Q-waves, hypertrophy or ST-depression

Table 1**Select Medications That Can Induce Orthostatic Hypotension****Antihypertensives**

Thiazide diuretics
Loop diuretics
Clonidine
Methyldopa
Reserpine
ACE inhibitors
Diltiazem
Nifedipine

Vasodilators

Nitrates
Hydralazine

Alpha-blocking agents

Terazosin
Doxazosin
Prazosin

Antidepressants

Tricyclic antidepressants
Trazodone
Selective serotonin reuptake inhibitors
Venlafaxine
Monoamine oxidase inhibitors

Antipsychotics

Atypical antipsychotics

Parkinson's disease drugs

Levodopa
Bromocriptine
Pergolide
Selegiline

Phenothiazine derivatives

Chlorpromazine
Promazine
Thioridazine

Miscellaneous

Quinidine
Barbiturates
Alcohol
Narcotics
Insulin
Phosphodiesterase-5 inhibitors
(sildenafil, tadalafil, vardenafil)
Vincristine

ACE: angiotensin-converting enzyme.

Source: Adapted from references 19, 20, 43.

**REAȚII ADVERSE CARE SEMNALIZEAZĂ
EVOLUȚIA DEFAVORABILĂ ȘI RISCURILE
EVOLUTIVE DISCOGNITIVE, DISMETABOLICE,
NEURODEGENERATIVE ȘI COMPORTAMENTALE**

Selected Agents Associated with Drug-Induced Movement Disorders

Acute and Tardive Akathisia

Antiemetics	Molindone
Droperidol	Phenothiazines (e.g., chlorpromazine, fluphenazine, mesoridazine, perphenazine, thioridazine, trifluoperazine)
Metoclopramide	
Prochlorperazine	
Promethazine	
Antiepileptics	Thioxanthenes (e.g., thiothexene)
Carbamazepine	Reserpine
Psychotropics	Selective serotonin-reuptake inhibitors
Lithium	
Neuroleptics	Tricyclic antidepressants
Haloperidol	

Acute and Tardive Dyskinesia

Antiemetics	Molindone
Metoclopramide	Phenothiazines (e.g., chlorpromazine, fluphenazine, mesoridazine, perphenazine, thioridazine, trifluoperazine)
Prochlorperazine	
Antiepileptics	
Phenytoin	
Psychotropics	Olanzapine (high dosage)
Amoxapine	Pimozide
Haloperidol	Risperidone (high dosage)
Lithium	Thioxanthenes (e.g., thiothexene)

Acute and Tardive Dystonia

Antiemetics	Molindone
Droperidol	Olanzapine (high dosage)
Metoclopramide	Phenothiazines (e.g., chlorpromazine, fluphenazine, mesoridazine, perphenazine, thioridazine, trifluoperazine)
Prochlorperazine	
Promethazine	
Psychotropics	Risperidone (high dose)
Amoxapine	
Neuroleptics	Thioxanthenes (e.g., thiothexene)
Haloperidol	


Parkinsonism

Antiemetics	Molindone
Droperidol	Olanzapine (high dosages)
Metoclopramide	Phenothiazines (e.g., chlorpromazine, fluphenazine, mesoridazine, perphenazine, thioridazine, trifluoperazine)
Prochlorperazine	
Promethazine	
Antiepileptics	Risperidone (high dosages)
Valproate	Thioxanthenes (e.g., thiothexene)
Cardiovascular agents	Vestibular sedatives
Alpha-Methyldopa	Cinnarizine and Flunarizine*
Reserpine	
Psychotropics	Miscellaneous
Amoxapine	Pimozide
Neuroleptics	Tetrabenazine*
Haloperidol	

Reacții adverse consemnate în ghidurile terapeutice

Efecte adverse	AP convențional	AP atipic
Simptome extrapiramidale	+ + +	+
Prolactinemie	+ +	+
Diskinezie tardivă	+ + +	+
Hipotensiune ortostatică	+ +	+
Prelungirea intervalului QT	+ + +	+
Sindrom metabolic	+	+ + +
Diabet zaharat	+	+ +
Moarte subită	+ +	+
Sindrom neuroleptic malign	+ + +	+
Sindrom serotoninergic*	+ -	+
Deteriorare cognitivă	+ + +	+ -

** risc amplificat de tratamente anterioare sau concomitente cu antidepressive serotoninergice.*



**Deteriorare cognitiva
Suicid
Patologie Duala
Agresivitate - Violenta**

RISC SUICIDAR

Pacientii cu schizofrenie au un risc de mortalitate precoce de pana la 40% prin doua cauze:

Suicid

Moarte ne-naturala

(Kahye Hor, 2010)

Pacientii spitalizati dupa primul episod de schizofrenie si care nu au luat in mod regulat medicatia antipsihotica (**aderenta scazuta**) au avut un risc de deces:

- de 12 ori mai mare, prin orice cauza
- de 37 ori mai mare, prin suicid.

(Tiihonen 2006)

Suicidul este puternic corelat cu urmatorii factori de risc: varsta tanara, sexul masculin, nivelul educational inalt, depresia, tentativele anterioare de suicid, comorbiditatile somatice (Kahye Hor, 2010).

There were 34 (30.9%) studies based on inpatient samples and outcomes.

- **The substance misuse domain was less strongly associated with violence risk, although it remained significant.**
- **The psychopathology and positive symptoms domains were more strongly associated with **violence risk**.**
- **The negative symptoms, neuropsychological, demographic, premorbid, **suicidality**, and treatment-related domains were associated with violence risk, but not significantly.**

Cel mai sever efect advers al
medicației psihotope este

NON-EFICACITATEA

și/sau

NON-ADERENȚA LA TRATAMENT

POTENȚIALE AFECȚIUNI COMORBIDE CORELATE CU TERAPIA ANTIPSIHOTICĂ ÎN TULBURĂRILE PSIHIATRICE MAJORE CARE INFLUENȚEAZĂ NEGATIV PROGNOSTICUL ȘI CRESC COSTURILE DE ÎNGRIJIRE:

- Diabet / hipoglicemie
- Afecțiuni gastrointestinale
- Afecțiuni pulmonare cronice
- Alcoolism / patologie duală
- Patologie cardio-cerebro-vasculară
- Afecțiuni stomatologice cronice

Table 2. Select Drug Categories and Drugs Associated With Hyperglycemia

Antibiotics
Quinolone
Gatifloxacin (also associated with hypoglycemia)
Levofloxacin
Atypical antipsychotics
Most Risky
Clozapine
Olanzapine
Intermediate
Paliperidone
Quetiapine
Risperidone
Least Risky
Aripiprazole
Ziprasidone
Unknown
Iloperidone
β-blockers*
Atenolol
Metoprolol
Propranolol
Corticosteroids
Calcineurin inhibitors
Cyclosporine
Sirolimus
Tacrolimus
Protease Inhibitors
Atazanavir
Darunavir
Fosamprenavir
Indinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
Thiazide and thiazide-like diuretics
Chlorthiazide
Chlorthalidone
Diazoxide
Hydrochlorothiazide
Indapamide
Methyclothiazide
Metolazone

**Note: Carvedilol and nebivolol are not associated with the development of hyperglycemia.*

Select Drug Categories and Drugs Associated With Hyperglycemia.

Antibioterapie

Antipsihotice atipice

Beta blocante

Corticosteroizi exogeni

Ciclosporina

Antivirale – HIV

Diuretice tiazidice

Abdur Rehman et al. Diabetes Spectr 2011;24:234-238

©2011 by American Diabetes Association



Condițiile comorbide metabolice determină modificări structurale cerebrale




- Hipoglicemia (diabet zaharat)
- Hipoxia
- Hipoperfuzia vasculară




Creșterea nivelului de glutamat declanșează reacții asociate cu modelul comportamentului exploziv de tip epileptiform

Comportamentul agresiv – crima



Pacientii cu psihoza au comis crime de 4 ori mai mult decat populatia generala



Factorii neurobiologici si psihofarmacologici care favorizeaza comportamentul criminal:

- Utilizarea medicatiei pentru afectiuni asociate
- Afectiuni comorbide de personalitate (personalitate antisociala)
- Lipsa aderenței la tratament
- Lipsa complianței la tratament

1. Tuninger 2001

2. Jan Volavka Treatment approaches to aggressive behavior in schizophrenia, cap 16 (2006) Crime and schizophrenia causes and cures

Exista suficiente argumente neurobiologice si psihofarmacologice care sa permita preventia secundara a comportamentelor agresive sau suicidare !

Crima de la metrou.



<http://www.gds.ro>

Pacient ucis intr-un sanatoriu de neuropsihiatrie din Botosani. Agresorul nu poate fi pedepsit, deoarece e bolnav psihic



<https://stirileprotv.ro>

Medicamentele care induc
hipoglicemia cresc riscul
comportamentelor violente și
suicidare

	Clinical Setting		
Ciabendoline	Chronic and acute: few had diabetes and renal insufficiency	Artesunate/artemisin/artemether	Acute: malaria and cerebral malaria
Clinafloxacin	Acute: pneumonia and sepsis	Chloroquineoxaline sulfonamide	Chronic: malignancy (mainly lung and colon)
Gatifloxacin	Acute: various infections	IGF-I	Chronic: diabetes or isolated GH deficiency
Glucagon	Chronic: endoscopy patients	Lithium	Chronic: postglucose hypoglycemia
Indomethacin	Chronic: infants with patent ductus arteriosus	Propoxyphene and	Chronic: renal insufficiency, few had
Pentamidine	Acute: infections in immunocompromised host		
Quinine	Acute: malaria and cerebral malaria		

Drug-induced hypoglycemia can be severe and cause significant morbidity. Prescribers should strive to avoid these adverse events particularly in elderly patients, patients with sepsis, renal or hepatic disease

Drug-induced hypoglycemia

Example	Mechanism of action
Insulin	Exogenous hyperinsulinaemia
Sulfonylureas	Increased insulin output
Meglitinides	
Salicylates	Impairment of gluconeogenesis
Pentamidine	β cell toxin
Quinine	Increased insulin output
Alcohol	Stimulates an exaggerated release of insulin by diverting blood flow to the endocrine part of the pancreas. Also impaired gluconeogenesis

Medicamentele care induc tulburări de
tip (pseudo)psihiatric –
posibilă sursă de erori de diagnostic și
tratament,
cu scăderea siguranței pacienților

An approach to drug induced delirium in the elderly

Box 1: Deliriant (drugs causing delirium)

Prescription drugs

- Central acting agents:
 - Sedative hypnotics (for example, benzodiazepines).
 - Anticonvulsants (for example, barbiturates).
 - Antiparkinsonian agents (for example, benztropine, trihexyphenidyl).
- Analgesics:
 - Narcotics (NB. meperidine*).
 - Non-steroidal anti-inflammatory drugs*.
- Antihistamines (first generation—for example, hydroxyzine).
- Gastrointestinal agents:
 - Antispasmodics.
 - H₂-blockers*.
- Antinauseants:
 - Scopolamine.
 - Dimenhydrinate.
- Antibiotics:
 - Fluoroquinolones*.
- Psychotropic medications:
 - Tricyclic antidepressants.
 - Lithium*.

- Cardiac medications:
 - Antiarrhythmics.
 - Digitalis*.
 - Antihypertensives (β -blockers, methyldopa)
- Miscellaneous:
 - Skeletal muscle relaxants.
 - Steroids.

Over the counter medications and complementary/alternative medications

- Antihistamines (NB. first generation—for example, diphenhydramine, chlorpheniramine).
- Antinauseants (for example, dimenhydrinate, scopolamine).
- Liquid medications containing alcohol.
- Mandrake.
- Henbane.
- Jimson weed.
- Atropa belladonna extract.

* Requires adjustment in renal impairment.

An approach to drug induced delirium in the elderly, K Alagiakrishnan, C A Wiens, Postgrad Med J 2004;80:388–393.

Some possible mechanisms of drug-induced depression

DRUG OR DRUG CLASS	POSSIBLE MECHANISM FOR DID
Nifedipine, other calcium channel blockers	Block slow influx of calcium into the cell, inhibiting calcium-dependent neurotransmitter release and reducing neurotransmitter amplification through the second-messenger system ²⁰
Benzodiazepines	Based on rodent studies: decreased release of serotonin in hippocampus (except with alprazolam) ²³
Exogenous corticosteroids	Based on rodent development studies: dexamethasone administration leads to deficits in the number and size of neural cells; reduced function of G-protein-coupled catecholaminergic or cholinergic receptors ²⁴
Varenicline	Displaces nicotine from acetylcholine receptors, produces low-to-moderate levels of dopamine release, and stimulates mesolimbic dopamine system. May upset the balance in cholinergic-adrenergic tone potentially leading to depression or mania ²⁵


DRUG-INDUCED RHABDOMYOLYSIS

Statins	Other Antilipid Agents	Psychiatric Agents	Abused Substances	Antihistamines	Other
Lovastatin	Ezetimibe	Amitriptyline	Alcohol	Diphenhydramine	Amphotericin B
Pravastatin	Bezafibrate	Amoxapine	Cocaine	Doxylamine	Arsenic
Simvastatin	Clozafibrate	Doxepin	Heroin/Opiates		Azathioprine
Fluvastatin	Ciprofibrate	Fluoxetine	Amphetamines		Carbon monoxide
Atorvastatin	Clofibrate	Fluphenazine	Methamphetamines		Halothane
Rosuvastatin	Gemfibrozil	Haloperidol	Lysergic acid diethylamide		Naltrexone
		Lithium	Phencyclidine		Quinidine
		Protriptyline			Penicillamine
		Perphenazine			Pentamidine
		Promethazine			Propofol
		Chlorpromazine			Salicylates
		Trifluoperazine			Succinylcholine
		Venlafaxine			Theophylline
		Benzodiazepines			Terbutaline
		Barbiturates			Thiazides
					Vasopressin

Eficiența medicației și lipsa reacțiilor adverse se corelează cu:

- **Factorii genetici, farmacogenomica**
- **Integritatea funcțională hepatică – hepatosteatoza alcoolică și non alcoolică**
- **Calitatea circulantă a proteinelor de legare a medicamentelor – hipoalbuminemia**
- **Integritatea funcției renale - clearance creatinină**
- **Integritatea BHE**

**Lipsa eficacității medicației și
prezența reacțiilor adverse se
corelează cu neurotoxicitatea**



*Schizophrenia,
Nature Reviews
Disease Primers,
Rene Kahn, 2015*

Patient with poor outcome

Patient with good outcome

Healthy comparison subject

